AMPD1 rs1109104: Muscle Fatigue and Recovery Genetics
The genetic variant rs1109104 is an intronic single nucleotide polymorphism located within the AMPD1 gene on chromosome 1. Situated near the classic nonsense mutation that causes myoadenylate deaminase deficiency, this variant is investigated for its potential correlation with exercise-induced muscle cramping, early neuromuscular fatigue, and recovery dynamics. Evidence linking rs1109104 directly to athletic performance and muscle traits remains limited and largely attributable to genetic linkage with nearby functional loci.
What each genotype means
Typical enzyme activity
This genotype represents the most common genetic sequence at this location. Research suggests this profile is associated with standard adenosine monophosphate deaminase 1 function in skeletal muscle, with no specific predisposition to exercise-related metabolic changes linked to this variant.
This is the most common genotype, found in the vast majority of individuals across all global populations.
Heterozygous variant carrier
You carry one copy of the variant allele, which is sometimes studied in the context of exercise-induced muscle fatigue. Current evidence is limited and mixed, as many individuals with this genotype remain asymptomatic and do not experience exercise intolerance.
Carried by approximately 1 in 5 to 1 in 6 people of European ancestry, with lower frequencies observed in other populations.
Potential exercise sensitivity
This genotype is associated with reduced or absent activity of the AMPD1 enzyme in skeletal muscle. While some studies link this to exercise-induced muscle pain, cramping, or early fatigue, many individuals with this genotype are entirely asymptomatic, suggesting that other factors influence whether symptoms manifest.
This genotype is relatively rare, occurring in approximately 1% to 2% of individuals of European ancestry.
Genomic Context of rs1109104
The single nucleotide polymorphism rs1109104 resides on chromosome 1 within an intronic region of the adenosine monophosphate deaminase 1 (AMPD1) gene. Introns are non-coding segments of DNA spliced out during messenger RNA processing, meaning rs1109104 does not directly alter the primary amino acid sequence of the encoded enzyme. Instead, it is situated adjacent to the well-characterized c.34C>T (rs17602729) nonsense variant, often referred to as the classic Q12X or Gly12Ter mutation. Because genetic variants located in close physical proximity along a chromosome tend to be inherited together as a block—a biological phenomenon called linkage disequilibrium—rs1109104 frequently acts as a tag or proxy marker tracking the broader genomic architecture of the locus. Catalog records and genetic surveys classify rs1109104 under complex physical performance traits, serving as an informative genomic milestone for exploring muscle bioenergetics.
Biological Role of the AMPD1 Gene
The AMPD1 gene provides the biological instructions for synthesizing the muscle-specific isoform of the enzyme adenosine monophosphate deaminase. Expressed predominately in skeletal muscle fibers, this enzyme catalyzes the deamination of adenosine monophosphate (AMP) into inosine monophosphate (IMP) and ammonia as part of the purine nucleotide cycle. During vigorous, high-intensity muscle contractions, ATP is rapidly consumed, leading to the accumulation of ADP and AMP. AMP deaminase helps clear accumulated AMP, shifting equilibrium toward the rapid generation of ATP and stabilizing cellular adenylate energy charge. When the enzyme is impaired or absent—most commonly due to premature termination codons in the gene—this metabolic clearance pathway is disrupted. This disruption leads to altered cellular purine recycling, reduced glycolytic flux, and reduced cellular energy availability during strenuous, repetitive physical exertion.
Exercise Phenotypes and Evidence Strength
Scientific investigations into AMPD1 variation have centered around neuromuscular phenotypes including exercise-induced muscle cramps, disproportionate muscle soreness, and early fatigue during strenuous anaerobic exercise. In individuals carrying disruptive AMPD1 alleles, impaired AMP deamination has been associated with decreased cardiorespiratory exercise capacity and prolonged post-exercise recovery. However, published literature categorizes the specific evidence linking rs1109104 independently to these phenotypes as limited. Most physiological and clinical associations, such as those noted in sports science and neuromuscular cohorts, are driven primarily by the functional c.34C>T nonsense variant rather than non-coding intronic changes. While some association studies observe statistical trends between rs1109104 and self-reported cramping or sprint fatigue, these findings are frequently mixed across different athletic disciplines and show considerable variation among non-athletic cohorts.
Population Frequency and Ancestry Patterns
The frequency of the rs1109104 variant displays notable differences across global biogeographic populations. In individuals of European ancestry, the minor allele frequency typically ranges between 10% and 12%, making heterozygous carriers relatively common in these cohorts. In contrast, East Asian, African, and Indigenous American populations present markedly lower frequencies, where the minor allele is rare or entirely absent in public genomic databases such as the Genome Aggregation Database (gnomAD). This pronounced ancestry-related divergence mirrors the evolutionary distribution observed for other common haplotypes within the AMPD1 locus. Because allele frequencies vary so widely across populations, any statistical inferences drawn from genetic association studies cannot be extrapolated universally and must be interpreted within an ancestry-specific context.
Practical Interpretation and Limitations
Understanding your rs1109104 genotype provides academic insight into muscle bioenergetics, but it cannot be used to diagnose a medical condition or predict physical athletic capability. A single non-coding variant within AMPD1 does not dictate your endurance threshold, determine muscle cramping risk, or indicate clinical myoadenylate deaminase deficiency. Athletic performance, muscle fatigue, and recovery kinetics are complex multifactorial outcomes influenced by hundreds of genes, cardiovascular fitness, training status, sleep, hydration, and nutritional habits. Genetic markers with limited evidence should never be used to make drastic changes to workout regimens or lifestyle routines. Anyone experiencing unexplained muscle pain, severe exercise intolerance, dark urine, or recurrent muscle breakdown should seek evaluation from a qualified physician rather than relying on consumer genetic data.
How common is this variant?
The minor allele frequency for rs1109104 is approximately 0.10 to 0.12 in European populations, whereas it is markedly rarer or nearly absent in East Asian and African ancestral groups according to population databases.
Frequently asked questions
Does having the rs1109104 variant mean I have AMPD deficiency?
No, carrying the rs1109104 variant does not mean you have AMP deaminase deficiency. The clinical condition is primarily caused by specific nonsense or splice-site mutations, such as the c.34C>T nonsense mutation, whereas rs1109104 is an intronic marker with limited and indirect clinical evidence.
Can this genetic variant cause severe muscle cramps during workouts?
While variations in the AMPD1 gene have been statistically correlated with exercise-induced cramping and fatigue in athletic studies, rs1109104 alone is not a proven direct cause of muscle cramps. Muscle cramping is influenced by hydration, electrolyte balance, physical conditioning, and environmental factors.
Does my rs1109104 genotype affect my athletic potential?
Genotype alone does not dictate whether someone can excel in endurance or power sports. While researchers study AMPD1 variation to understand skeletal muscle bioenergetics, training, nutrition, sleep, and overall cardiovascular health play far larger roles in athletic outcomes.
Should I modify my exercise routine based on my rs1109104 result?
No modifications to your fitness or medical routine should be made based solely on this single variant. If you regularly experience disproportionate fatigue, prolonged muscle weakness, or severe post-exercise pain, you should consult a licensed healthcare professional for a comprehensive evaluation.
Sources & further reading
Educational information only, last refreshed 9/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1109104?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in AMPD1
Variant in the AMPD1 promoter region associated with skeletal muscle adenosine monophosphate deaminase expression, post-exercise fatigue, and cardiorespiratory fitness response.
This SNP is associated with autism risk and may influence physiological responses to stress-related environmental factors.